CTOs on the Move

SwanBio Therapeutics

www.swanbiotx.com

 
With offices in Philadephia and Boston, SwanBio Therapeutics is developing leading-edge therapies to deliver dramatic clinical efficacy for the treatment of neurological diseases. We are driven by an unrelenting passion to solve difficult challenges, and a belief that meaningful discovery is borne of curiosity, collaboration, and compassion. Founded by proven industry leaders with a commitment to positively impacting the lives of people with neurological diseases, SwanBio merges clinical, scientific and drug commercialization expertise.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.swanbiotx.com
  • 150 Monument Road Suite 207
    Bala Cynwyd, PA USA 19004
  • Phone: 610.557.0600

Executives

Name Title Contact Details
Scott McMillan
Chief Technical Officer Profile

Funding

SwanBio Therapeutics raised $52M on 04/23/2020

Similar Companies

Verve Therapeutics

Verve Therapeutics is a biotechnology company focused on discovering and developing therapies that safely edit the genomes of adults to confer lifelong protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide. Headquartered in Cambridge, Mass., with a research facility in Philadelphia.

TransMolecular

TransMolecular, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders

Mission Bio

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics.

Readcoor

ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.